148 related articles for article (PubMed ID: 26576861)
1. Investigational drugs for T-cell lymphoma.
Ghez D; Danu A; Ribrag V
Expert Opin Investig Drugs; 2016; 25(2):171-81. PubMed ID: 26576861
[TBL] [Abstract][Full Text] [Related]
2. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
7. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
[TBL] [Abstract][Full Text] [Related]
8. [Molecular pathogenesis of peripheral T-cell lymphoma (1): angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified and anaplastic large cell lymphoma].
Couronné L; Bastard C; Gaulard P; Hermine O; Bernard O
Med Sci (Paris); 2015 Oct; 31(10):841-52. PubMed ID: 26481023
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.
Laribi K; Alani M; Truong C; Baugier de Materre A
Oncologist; 2018 Sep; 23(9):1039-1053. PubMed ID: 29674443
[TBL] [Abstract][Full Text] [Related]
10. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
11. Genetic Landscape and Classification of Peripheral T Cell Lymphomas.
Sandell RF; Boddicker RL; Feldman AL
Curr Oncol Rep; 2017 Apr; 19(4):28. PubMed ID: 28303495
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies in peripheral T cell lymphoma.
Jagadeesh D; Smith MR
Discov Med; 2013 Jun; 15(85):367-78. PubMed ID: 23819951
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.
Orlova A; Wingelhofer B; Neubauer HA; Maurer B; Berger-Becvar A; Keserű GM; Gunning PT; Valent P; Moriggl R
Expert Opin Ther Targets; 2018 Jan; 22(1):45-57. PubMed ID: 29148847
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.
Epstein-Peterson ZD; Horwitz SM
Semin Hematol; 2021 Apr; 58(2):78-84. PubMed ID: 33906725
[TBL] [Abstract][Full Text] [Related]
16. PTCL therapies: a review of treatment and outline of novel therapies.
Khan N; Cheson BD
Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
[TBL] [Abstract][Full Text] [Related]
17. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
18. Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G; Griessl R; Sifft E; Taylor N; Kenner L; Greil R; Merkel O
Expert Opin Drug Discov; 2012 Dec; 7(12):1149-63. PubMed ID: 22998641
[TBL] [Abstract][Full Text] [Related]
19. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]